AZN Analysis & News - AstraZeneca Group plc | Seeking Alpha

AZN

AstraZeneca Group plc | NYSE

1d 5d 1m 6m 1y 5y 10Y Advanced Chart

52wk high:36.75

52wk low:28.43

EPS:1.20

PE (ttm):29.32

Div Rate (ttm):1.90

Yield (ttm):5.41%

Market Cap:$88.97B

Volume:

Analysis

How Will This Unexpected War For First-Line Lung End?
Zach Hartman•Mon, Apr. 16
AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market
Terry Chrisomalis•Thu, Mar. 22
I've Sold AstraZeneca Because Of Its Rising Share Price And Weak Results
John Kingham•Fri, Mar. 9
AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In
Terry Chrisomalis•Mon, Feb. 19
Biotech Analysis Central Pharma News: Galectin's Failure, Revance's Positive Results, Novo Nordisk's FDA Win
Terry Chrisomalis•Dec. 6, 2017
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered
Avisol Capital Partners•Nov. 15, 2017
Your Daily Pharma Scoop: AstraZeneca's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Avisol Capital Partners•Oct. 18, 2017
Exploring AstraZeneca's Two-Pronged Assault On Lung Cancer
Zach Hartman•Oct. 18, 2017
Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi
Avisol Capital Partners•Oct. 10, 2017
AstraZeneca: Is It Investable After Imfinzi Failure?
Avisol Capital Partners•Sep. 8, 2017
AstraZeneca: Tremendous Upside Potential
Elderberry Investments•Aug. 22, 2017
AstraZeneca, Time To Expand The Operation
Terry Chrisomalis•Aug. 18, 2017
After AstraZeneca's 'Disaster', What's In Store For Their Immune Checkpoint Program?
Zach Hartman•Aug. 3, 2017
AstraZeneca Stages Major Lung Cancer Comeback
Terry Chrisomalis•Aug. 2, 2017
AstraZeneca Gets The Bad News
Derek Lowe•Aug. 2, 2017

News

Zai Lab in-licenses Entasis Therapeutics' broad-spectrum antibiotic in Asia-Pacific; shares up 3%
SA News•Today, 11:05 AM
FDA accepts Sanofi Pasteur's marketing application for expanded use of flu vaccine
SA News•Today, 9:45 AM•1 Comment
G1 Therapeutics initiates Phase 1b/2 clinical trial of G1T38 in combination with Tagrisso for EGFR-mutant NSCLC
SA News•Mon, Apr. 16
Bristol-Myers slips 1% premarket on lack of Pfizer interest
SA News•Thu, Apr. 12•21 Comments
AstraZeneca licenses NASH candidate from Ionis Pharma
SA News•Mon, Apr. 9•11 Comments
Clovis Oncology +3.8% on approved expansion for Rubraca
SA News•Fri, Apr. 6•4 Comments
CMS finalizes policies to reduce drug costs for Medicare beneficiaries
SA News•Tue, Apr. 3•44 Comments
FDA OKs AstraZeneca's Bydureon with basal insulin for T2D
SA News•Tue, Apr. 3•1 Comment
The EMA accepts regulatory submission for LYNPARZA in BRCA-mutated HER2-negative metastatic breast cancer
SA News•Tue, Apr. 3
FDA accepts AstraZeneca's application for moxetumomab pasudotox
SA News•Tue, Apr. 3
Compugen inks antibody development deal with AstraZeneca; shares ahead 11% premarket
SA News•Mon, Apr. 2•2 Comments
Myriad Genetics BRACAnalysis test OK'd in Japan as companion diagnostic with Lynparza
SA News•Mon, Apr. 2•3 Comments
FDA working on policies to boost biosimilars
SA News•Wed, Mar. 28•48 Comments
Big Pharma in the green as bargain hunters move in
SA News•Wed, Mar. 28•58 Comments
AstraZeneca crosses the finish line in Europe with hyperkalemia drug ZS-9
SA News•Thu, Mar. 22•5 Comments

Partner News

FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
at Zacks.com (Mon, 11:19AM)
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
at Zacks.com (Thu, 11:49AM)
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
at Zacks.com (Apr 10, 2018)
How AstraZeneca’s 1Q18 Shook Out
at MarketRealist.com (Apr 9, 2018)
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
at Zacks.com (Apr 4, 2018)
US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia
at TheStreet (Apr 3, 2018)
AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment
at TheStreet (Mar 19, 2018)
What Analysts Recommend for AstraZeneca in March 2018
at MarketRealist.com (Mar 14, 2018)
What Analysts Expect for AstraZeneca Going Forward
at MarketRealist.com (Mar 14, 2018)
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
at Zacks.com (Mar 13, 2018)